210 related articles for article (PubMed ID: 29729809)
21. PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA: Impact on Clinical Outcomes.
Stewart S; Yeong JL; Virgili G; Azuara-Blanco A; Lois N
Retina; 2020 May; 40(5):919-927. PubMed ID: 30789463
[TBL] [Abstract][Full Text] [Related]
22. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data.
Gonzalez VH; Campbell J; Holekamp NM; Kiss S; Loewenstein A; Augustin AJ; Ma J; Ho AC; Patel V; Whitcup SM; Dugel PU
Am J Ophthalmol; 2016 Dec; 172():72-79. PubMed ID: 27644589
[TBL] [Abstract][Full Text] [Related]
23. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
24. Real-life experience of ranibizumab for diabetic macular edema in Taiwan.
Tsai MJ; Hsieh YT; Peng YJ
Int Ophthalmol; 2019 Jul; 39(7):1511-1522. PubMed ID: 29926364
[TBL] [Abstract][Full Text] [Related]
25. Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study.
Farinha C; Martins A; Neves A; Soares R; Ruão M; Ornelas M; Neves P; Gomes Rodrigues F; Coelho C; Silva R
Ophthalmologica; 2019; 241(1):1-8. PubMed ID: 29886497
[TBL] [Abstract][Full Text] [Related]
26. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890
[TBL] [Abstract][Full Text] [Related]
27. Full thickness macular hole following intravitreal ranibizumab injection for diabetic macular edema; a rare complication or coincidence?
Arifoglu HB; Hashas AS; Ersekerci TL; Atas M
Indian J Ophthalmol; 2015 Apr; 63(4):362-3. PubMed ID: 26044487
[No Abstract] [Full Text] [Related]
28. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
29. THREE-YEAR OUTCOMES IN A RANDOMIZED SINGLE-BLIND CONTROLLED TRIAL OF INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA.
Lafuente M; Ortín L; Argente M; Guindo JL; López-Bernal MD; López-Román FJ; Domingo JC; Lajara J
Retina; 2019 Jun; 39(6):1083-1090. PubMed ID: 29474306
[TBL] [Abstract][Full Text] [Related]
30. Visual outcomes following anti-VEGF therapy in patients with DME.
Panigrahi PK; Patro M
Indian J Ophthalmol; 2024 Jul; 72(Suppl 4):S718. PubMed ID: 38953138
[No Abstract] [Full Text] [Related]
31. Monthly Versus Treat-and-Extend Ranibizumab for Diabetic Macular Edema: A Prospective, Randomized Trial.
Eichenbaum DA; Duerr E; Patel HR; Pollack SM
Ophthalmic Surg Lasers Imaging Retina; 2018 Nov; 49(11):e191-e197. PubMed ID: 30457655
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema.
Eriş E; Perente I; Vural E; Vural A; Seymen Z; Celebi ARC; Erdogan G; Ozkaya A; Artunay O
Int Ophthalmol; 2019 Jul; 39(7):1575-1580. PubMed ID: 29943100
[TBL] [Abstract][Full Text] [Related]
33. Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection?
Uyar E; Ulaş F; Alkan Y
Curr Eye Res; 2021 Feb; 46(2):248-254. PubMed ID: 32635750
[TBL] [Abstract][Full Text] [Related]
34. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.
Chang CK; Cheng CK; Peng CH
Eye (Lond); 2017 May; 31(5):762-770. PubMed ID: 28106889
[TBL] [Abstract][Full Text] [Related]
35. Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.
Wong Y; Steel DHW; Habib MS; Stubbing-Moore A; Bajwa D; Avery PJ;
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):733-742. PubMed ID: 27957600
[TBL] [Abstract][Full Text] [Related]
36. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema.
Moshfeghi AA; Shapiro H; Lemmon LA; Gune S
Ophthalmol Retina; 2018 Feb; 2(2):86-90. PubMed ID: 31047350
[TBL] [Abstract][Full Text] [Related]
37. Impact of serous retinal detachment on the efficacy of ranibizumab in diabetic macular oedema.
Qu-Knafo LM; Fajnkuchen F; Sarda V; Boubaya M; Levy V; Chaine G; Giocanti-Auregan A
Acta Ophthalmol; 2017 Aug; 95(5):e434-e435. PubMed ID: 26823130
[No Abstract] [Full Text] [Related]
38. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU
Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914
[TBL] [Abstract][Full Text] [Related]
39. OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.
Santos AR; Costa MÂ; Schwartz C; Alves D; Figueira J; Silva R; Cunha-Vaz JG
Retina; 2018 Jun; 38(6):1110-1119. PubMed ID: 28613220
[TBL] [Abstract][Full Text] [Related]
40. Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema.
Koç İ; Kadayıfçılar S; Eldem B
Ophthalmologica; 2018; 239(2-3):85-93. PubMed ID: 29050009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
